TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Request for additional analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: drug liking Emax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: desire to take the drug again
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: peak oxycodone plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA(1c) levels as a risk factor for type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy and safety of ticagrelor compared to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of clinically active trachoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in post-test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interexaminer reliability for dental plaque assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interexaminer reliability for dental caries assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for delta HR/BT with cut-off ≥ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity for delta HR/BT with cut-off ≥ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value for delta HR/BT with cut-off ≥ 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Link to 30-day postoperative patient cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Methicillin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: increased aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to complete resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of intraoperative ultrasound for N staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of intraoperative ultrasound for N staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall accuracy of intraoperative ultrasound for N staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of self-induced vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disturbed attitudes toward eating and weight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention rate of GIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound transmission speed in the Achilles tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (reduction of ≥3 points in SCCAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoscopic remission (partial Mayo score ≤1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: MCCB composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attention/vigilance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in zBMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adherence to pharmacotherapy for smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in voiding patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in UF parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath test normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of TAP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-increase of markers (relapse)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of BSP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ease of use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: acceptability and tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUCINF for apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean T½ for apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Health Change (PHC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severe adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative net occlusal wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restoration performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: color matching improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of antivenom dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular mortality at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Ceased to react to the highest allergen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in response threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low frequency (LF) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Low-to-high frequency (LF/HF) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Long-term seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: QOLIE-31 questionnaire improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: metabolic acidosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: success of insemination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: incidence of tourniquet pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: block performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of paraesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Community-acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Nonbacteremic and noninvasive community-acquired pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Invasive pneumococcal disease
Endpoint domain: Adverse events/effects
Primary endpoint: Hemodynamic values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gas exchange parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects attributable to lipid emulsions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean ICSI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PORIS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of flow‐mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of progression of carotid intima‐media thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Polymegathism index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General perceived self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stability of the tear film
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QRS prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of plasma coagulation factor IX activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: risk of pin tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency response self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Emergency response behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of FTC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: spontaneous myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in the number of FOG episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in motor performance (walking and balance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in quality-of-life assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response rate to fluoxetine vs placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of individuals with ocular melanocytic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intra‐individual change in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean relapse ratio 1 year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Core Total improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational Disruptiveness score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Incidence of malnutrition
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving HbA1c <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: elastic stretch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elastic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain/pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in A(1c) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lapse to recover protective reflexes and motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: allergen threshold levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: late-phase reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Glasgow Outcome Scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Preference for ED care over primary care for child injuries
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trust in ED doctors for treatment of injuries
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Referral rates to ED by GP for injured vs ill children
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of labor stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quit intentions
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Muscular symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Endometrial cancer risk
Endpoint domain: Mortality/survival
Primary endpoint: Reflux resolution or downgrading to grade I‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACTH responses to citalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in loss of usual functioning time
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: ≥50% reduction in YMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predicted probabilities of unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of correctly placed tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average error from the mean in blood volume estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PAI‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: t‐PA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement of exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in peak oxygen consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived health and overall life situation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voice Handicap Index (VHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge level on diet restrictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of compliance with diet restrictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of bowel cleanness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent total oral clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent volume of distribution of the central compartment (V(1))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first‐order absorption rate constant (k(a))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: participant satisfaction with teaching format
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma glucose content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HoNOSCA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of interpreting genetic diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracortical facilitation (ICF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean number of symptomatic UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants with at least 1 symptomatic UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Median time to the first UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Differential index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 20-m sprint times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average jump height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TG concentrations at birth and 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thiocyanate concentrations at birth and 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Preparation for employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: lesion complete response rate for total AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: pain during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Contrast Sensitivity (CS) at 3 cycles/degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: classification error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean success rate graft take
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Low density lipoprotein (LDL-C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tissue factor (TF) expression in circulating monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact lens case contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: modified Action Research Arm Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean visual acuity gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in erectile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increase in total plasma testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative respiratory compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immediate postoperative Pao(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CVA (Cervical Vertebral Angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRA (Cervical Range of Motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior/posterior ratio of plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of consultations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Correct self-injection steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMT nephropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of speech perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of social restriction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Mean LDL size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: HDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Rate of osteoporosis screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of dependence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy for diagnosing GIM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate memory improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Free of hospitalization for any cause at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Risk of musculoskeletal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inverse correlation between post-diagnosis vitamin D levels and CD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial rejuvenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes